Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT Total Current Liabilities

All obligations due within one year.

Sagimet Biosciences Inc.NASDAQ: SGMT

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities falls 26.2% from a year ago

Total current liabilities stood at $5.3M at the end of Q1 FY2026, down 26.2% from a year earlier and up 3.8% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.

Context

  • Total current liabilities amounted to 4.9% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -26.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.3M+3.8% QoQ
Last fiscal yearDec 2025
$5.1M+14.5% YoY
Year agoMar 2025
$7.18M-26.2% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.2%——
1 year+14.5%——
3-year CAGR-1.1%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
5.1M USD
Year-over-year change
+14.5%
4-year CAGR
+20.2%

Total Current Liabilities vs competitors

How SGMT compares with its peers on the latest reported figures

  • SGMT's Mar 2026 total current liabilities of $5.3M is the lowest of the 11 companies compared; the peer median is $26.28M.
  • Its year-over-year change of -26.2% is the 8th highest of 11, against a peer median of -14.4%.
  • Total current liabilities amounts to 4.9% of total assets for SGMT, versus a peer median of 13.2%.
SGMT Competitors Peer median
Total Current Liabilities for SGMT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$4.97B +97278.1%+7.7%2.3%
FHTXFoghorn Therapeutics Inc.Mar 2026$64.4M -9.7%+2.7%29.0%
ASMBAssembly Biosciences, Inc.Mar 2026$35M -24.9%+44.1%14.9%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$34.37M -30.4%-34.1%14.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$33.37M +53.4%+29.1%12.5%
TRDAEntrada Therapeutics, Inc.Mar 2026$19.2M +4.1%+3.6%5.7%
VYGRVoyager Therapeutics, Inc.Mar 2026$17.45M -56.6%-28.5%8.0%
HUMAHumacyte, Inc.Mar 2026$16.19M -19.2%-2.1%14.6%
ACHVAchieve Life Sciences, Inc.Mar 2026$11.83M +66.0%-25.1%35.7%
ZURAZura Bio LimitedMar 2026$11.75M -44.3%-5.7%5.1%
SGMTSagimet Biosciences Inc.Mar 2026$5.3M -26.2%-1.1%4.9%
Peer median (excluding SGMT) $26.28M-14.4%+0.3%13.2%

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents56.73M158K75.14M75.84M35.02M
Short-term Investments032.19M19.76M75.41M78.1M
Net Receivables00000
Inventory00000
Other Current Assets1.51M34K397K463K481K
Total Current Assets58.66M32.79M96.65M152.77M116.4M
Property, Plant & Equipment (Net)342K212K73K77K78K
Goodwill00000
Intangible Assets00000
Long-term Investments0007.41M0
Tax Assets00000
Other Non-current Assets27K27K000
Total Non-current Assets369K239K73K7.49M78K
Total Assets59.03M33.03M96.72M160.26M116.48M
Account Payables761K1.13M186K1.43M1.31M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities185K57K556K5K27K
Total Current Liabilities2.44M5.28M5.65M4.45M5.1M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities214.63M214.62M000
Total Non-current Liabilities214.85M214.7M000
Total Liabilities217.29M219.98M5.65M4.45M5.1M
Common Stock1K1K2K3K3K
Retained Earnings(191.37M)(221.87M)(249.74M)(295.31M)(346.35M)
Accumulated OCI0(84K)30K230K120K
Other Stockholders Equity00(0)(0)0
Minority Interest00000
Total Equity(158.26M)(186.95M)91.07M155.81M111.38M
Total Debt348K211K65K78K78K
Net Debt(56.38M)53K(75.07M)(75.76M)(34.94M)

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.